DOP2002000431A - Vacunación en dosis unica con mycoplasma hyopneumoniae - Google Patents

Vacunación en dosis unica con mycoplasma hyopneumoniae

Info

Publication number
DOP2002000431A
DOP2002000431A DO2002000431A DO2002000431A DOP2002000431A DO P2002000431 A DOP2002000431 A DO P2002000431A DO 2002000431 A DO2002000431 A DO 2002000431A DO 2002000431 A DO2002000431 A DO 2002000431A DO P2002000431 A DOP2002000431 A DO P2002000431A
Authority
DO
Dominican Republic
Prior art keywords
vaccine
hyo
mycoplasma hyopneumoniae
dose vaccination
present
Prior art date
Application number
DO2002000431A
Other languages
English (en)
Inventor
Robin Lee Keich
Lise Grace Sabbadini
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23168589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2002000431(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of DOP2002000431A publication Critical patent/DOP2002000431A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/87—Mycoplasma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a procedimientos para el tratamiento o prevención de una enfermedad o trastorno en un animal causada por infección por Mycoplasma hyopneumoniae M. hyo mediante la administración a un animal, a aproximadamente los tres 3 a diez 10 días de edad, de una dosis única de una cantidad efectiva de una vacuna de M. hyo. La vacuna de M. hyo puede ser una preparación de células vivas modificadas o de células inactivadas parcial o . completamente, una vacuna de subunidades o una vacuna de ácido nucleico o ADN. La vacuna de M. hyo administrada de acuerdo con la presente invención puede producirse de manera sintética o recombinante.
DO2002000431A 2001-07-02 2002-06-26 Vacunación en dosis unica con mycoplasma hyopneumoniae DOP2002000431A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30263601P 2001-07-02 2001-07-02

Publications (1)

Publication Number Publication Date
DOP2002000431A true DOP2002000431A (es) 2003-01-15

Family

ID=23168589

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2002000431A DOP2002000431A (es) 2001-07-02 2002-06-26 Vacunación en dosis unica con mycoplasma hyopneumoniae

Country Status (42)

Country Link
US (3) US6846477B2 (es)
EP (3) EP2842569B1 (es)
JP (1) JP2005515162A (es)
KR (1) KR20040030785A (es)
CN (3) CN1551781B (es)
AP (1) AP2003002937A0 (es)
AR (1) AR034678A1 (es)
AT (1) ATE412426T2 (es)
AU (1) AU2002309109B2 (es)
BG (1) BG66481B1 (es)
BR (1) BR0210804A (es)
CA (1) CA2451626C (es)
CY (1) CY1108749T1 (es)
CZ (1) CZ305781B6 (es)
DE (1) DE60229666D1 (es)
DK (3) DK1474067T4 (es)
DO (1) DOP2002000431A (es)
EA (1) EA009901B1 (es)
ES (3) ES2729579T3 (es)
GT (1) GT200200138A (es)
HK (1) HK1207584A1 (es)
HR (1) HRP20031079A2 (es)
HU (1) HU230246B1 (es)
IL (1) IL159349A0 (es)
IS (1) IS7076A (es)
MA (1) MA27047A1 (es)
MX (1) MXPA03011599A (es)
NO (1) NO342654B1 (es)
NZ (1) NZ530106A (es)
OA (1) OA12638A (es)
PA (1) PA8549701A1 (es)
PE (1) PE20030285A1 (es)
PL (1) PL209773B1 (es)
PT (3) PT1474067E (es)
SK (1) SK288010B6 (es)
TN (1) TNSN03155A1 (es)
TW (1) TWI329514B (es)
UA (1) UA78707C2 (es)
UY (1) UY27366A1 (es)
WO (1) WO2003003941A2 (es)
YU (1) YU102203A (es)
ZA (1) ZA200309698B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
WO2006056841A1 (en) * 2004-11-24 2006-06-01 Pharmacia & Upjohn Company Llc Multiple-strain mycoplasma hyopneumoniae vaccines
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
HUE054868T2 (hu) 2005-12-29 2021-10-28 Boehringer Ingelheim Animal Health Usa Inc Multivalens PVC2 immunogén készítmények és eljárások ezek elõállítására
ES2553253T3 (es) 2005-12-29 2015-12-07 Boehringer Ingelheim Vetmedica, Inc. Uso de una composición inmunogénica de PCV2 para reducir los síntomas clínicos en cerdos
KR20080100384A (ko) * 2006-03-03 2008-11-17 메리얼 리미티드 마이코플라즈마 하이오뉴모니아에 백신
WO2008064299A2 (en) * 2006-11-22 2008-05-29 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing porcine circovirus-associated disease outbreaks
EP2859900A1 (en) * 2006-12-11 2015-04-15 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
DK2481420T3 (da) 2006-12-15 2019-05-06 Boehringer Ingelheim Animal Health Usa Inc Enkeltdosis-anti-PCV2-svinevaccine
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
WO2009061798A1 (en) 2007-11-06 2009-05-14 Wyeth Mycoplasma hyopneumoniae avirulent -adjuvanted live vaccine
KR20100103535A (ko) * 2007-12-31 2010-09-27 베링거잉겔하임베트메디카인코퍼레이티드 외래 아미노산 삽입물을 갖는 ｐｃｖ２ ｏｒｆ２ 바이러스 유사 입자
CN101236206B (zh) * 2008-01-17 2014-10-15 中国兽医药品监察所 一种猪肺炎支原体重组抗原elisa检测试剂盒
KR20100113582A (ko) * 2008-01-23 2010-10-21 베링거잉겔하임베트메디카인코퍼레이티드 Ｐｃｖ2 마이코플라즈마 히오뉴모니에 면역원성 조성물 및 당해 조성물의 생산 방법
US8444989B1 (en) * 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
NZ709547A (en) 2008-06-27 2017-01-27 Zoetis Services Llc Novel adjuvant compositions
US9539209B2 (en) 2009-06-04 2017-01-10 National Institute Of Infectious Diseases Vaccine for mycoplasma infection
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
DK2569007T3 (en) 2010-05-11 2016-01-25 Intervet Int Bv VACCINE AGAINST Mycoplasma hyopneumoniae SUITABLE FOR ADMINISTRATION IN PRESENCE OF maternally derived antibodies
CA3255684A1 (en) * 2010-07-26 2025-05-23 Qu Biologics Inc. Immunogenic anti-inflammatory compositions
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
WO2012025612A1 (en) * 2010-08-27 2012-03-01 Intervet International B.V. Potency test for vaccine formulations
US9687544B2 (en) 2011-04-18 2017-06-27 Ceva Sante Animale Veterinary vaccine
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
KR102355614B1 (ko) 2012-12-28 2022-01-27 베링거잉겔하임베트메디카게엠베하 마이코플라스마 항원을 포함하는 면역원성 조성물
PT2938747T (pt) 2012-12-28 2019-08-01 Boehringer Ingelheim Vetmedica Gmbh Método de preparação de uma vacina de micoplasma
EP3733690A1 (en) * 2013-02-05 2020-11-04 Agricultural Technology Research Institute Anti-mycoplasma spp. subunit vaccine
CN104338125A (zh) * 2013-07-29 2015-02-11 普莱柯生物工程股份有限公司 一种猪肺炎支原体抗原在预防和治疗猪呼吸道疾病综合征方面的应用
KR20190009840A (ko) 2013-09-19 2019-01-29 조에티스 서비시즈 엘엘씨 유성 아쥬반트
JP6778104B2 (ja) 2013-10-02 2020-10-28 ベーリンガー・インゲルハイム・アニマル・ヘルス・ユーエスエー・インコーポレイテッドＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ａｎｉｍａｌ Ｈｅａｌｔｈ Ｕｓａ Ｉｎｃ． Ｐｃｖ２ ｏｒｆ２タンパク質変種および前記を含むウイルス様粒子
RU2646137C2 (ru) 2013-11-21 2018-03-01 Эгрикалчурал Текнолоджи Рисерч Инститьют КОМПОЗИЦИЯ ПО ПРЕДУПРЕЖДЕНИЮ ИНФЕКЦИИ Mycoplasma spp.
CN105012948B (zh) * 2014-04-18 2019-07-30 普莱柯生物工程股份有限公司 一种疫苗组合物及其应用
CN104248753B (zh) * 2014-05-15 2017-07-28 普莱柯生物工程股份有限公司 一种疫苗组合物及其应用
BR102014014727B1 (pt) * 2014-06-16 2018-04-03 Ouro Fino Saúde Animal Ltda COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae, GENE SINTÉTICO CODIFICANTE DO COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae, COMPOSIÇÃO ANTIGÊNICA, PROCESSO DE OBTENÇÃO DE UM COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae
US9814769B2 (en) 2014-09-30 2017-11-14 Qatar University Vaccines against pathogenic Escherichia coli and methods of using the same
DK3244920T5 (da) 2015-01-16 2024-10-07 Zoetis Services Llc Mund- og klovsyge-vaccine
KR20160099223A (ko) * 2015-02-12 2016-08-22 강원대학교산학협력단 마이코플라스마 하이오뉴모니애 박테린 백신 및 이의 제조방법
EP3498847A4 (en) * 2016-08-12 2020-03-04 Innovac VACCINE COMPOSITION FOR PREVENTING PORCINE MYCOPLASMA INFECTIONS WITH RECOMBINANT PROTEIN
RU2668799C1 (ru) * 2017-09-08 2018-10-02 Эгрикалчурал Текнолоджи Рисерч Инститьют Субъединичная вакцина против mycoplasma spp.
CN108101969A (zh) * 2017-11-13 2018-06-01 南京大爻网络科技有限公司 一种与猪支原体肺炎相关的抗原及其应用
RU2695679C1 (ru) * 2018-09-11 2019-07-25 Эгрикалчурал Текнолоджи Рисерч Инститьют Субъединичная вакцина против mycoplasma spp.
RU2759427C2 (ru) * 2019-07-08 2021-11-12 Эгрикалчурал Текнолоджи Рисерч Инститьют Субъединичная вакцина против mycoplasma spp
CN117305192A (zh) * 2023-12-01 2023-12-29 北京瑞阳瑞泰生物科技有限公司 一种猪肺炎支原体rt02株、疫苗组合物及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0283840A3 (en) * 1987-03-26 1989-08-09 Ml Technology Ventures, L.P. Mycoplasma hyopneumoniae antigen and uses therefor
US5252328A (en) * 1987-03-26 1993-10-12 Martin Marietta Energy Systems, Inc. Mycoplasma hyopneumoniae antigen and uses therefor
DE3881993T2 (de) 1987-09-18 1993-09-30 Akzo Nv Mycoplasma-Impfstoff.
AU7682091A (en) 1990-04-02 1991-10-30 Synergen, Inc. Polypeptides useful in diagnosis of and treatment against mycoplasma infections in animals
JP3187419B2 (ja) 1990-05-29 2001-07-11 アメリカン・サイアナミド・カンパニー ブタ肺炎ワクチンおよびその製造方法
US6113916A (en) * 1990-05-29 2000-09-05 American Cyanamid Company Method of enhancing cell mediated immune responses
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
EP0475185A1 (en) 1990-08-27 1992-03-18 Nippon Flour Mills Co., Ltd. DNA's encoding surface antigen of mycoplasma hyopneumoniae, DNA fragments for primer, recombinant antigenic peptides and diagnostic method of mycoplasmal pneumoniae of swine using same
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
ATE273022T1 (de) * 1992-09-28 2004-08-15 Wyeth Corp Verfahren zur verstärkung zellularer immunantworten
US5530874A (en) 1993-02-02 1996-06-25 3Com Corporation Network adapter with an indication signal mask and an interrupt signal mask
WO1995009870A1 (en) 1993-10-07 1995-04-13 Iowa State University Research Foundation, Inc. Characterization of mycoplasma hyopneumoniae adhesins
CA2189979C (en) 1994-05-10 2011-04-19 Hsien-Jue Chu Improved modified live brsv vaccine
US5788962A (en) 1995-01-17 1998-08-04 The Curators Of The University Of Missouri DNA sequences coding for mycoplasma hyopneumoniae surface antigens, corresponding proteins and use in vaccines and diagnostic procedures
AUPN178995A0 (en) 1995-03-16 1995-04-13 University Of Melbourne, The Antigen composition
DE69730152T2 (de) 1996-09-30 2005-11-03 University Of Arkansas, Fayetteville Verfahren zur erzeugung aktiver immunität durch vakzinkonjugate
EP0846468B1 (en) 1996-12-05 2004-06-09 Akzo Nobel N.V. Non-virulent mycoplasma synoviae and vaccine thereof
CA2311759A1 (en) 1997-11-26 1999-06-03 Tsungdas Hsu Recombinant mycoplasma hyopneumoniae vaccine
AU6128900A (en) * 1999-09-29 2001-04-05 Pfizer Products Inc. Nucleic acids and proteins of the mycoplasma hyopneumoniae mph3 gene and uses thereof
US6585981B1 (en) * 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs

Also Published As

Publication number Publication date
WO2003003941A2 (en) 2003-01-16
CN102872456A (zh) 2013-01-16
DK2027873T3 (en) 2015-11-09
BR0210804A (pt) 2005-05-03
AP2003002937A0 (en) 2003-12-31
HUP0400434A2 (en) 2007-08-28
CZ305781B6 (cs) 2016-03-16
USRE44399E1 (en) 2013-07-30
PL209773B1 (pl) 2011-10-31
HRP20031079A2 (en) 2005-10-31
EA009901B1 (ru) 2008-04-28
US20050013823A1 (en) 2005-01-20
YU102203A (sh) 2006-05-25
CY1108749T1 (el) 2014-04-09
MXPA03011599A (es) 2005-03-07
ATE412426T2 (de) 2008-11-15
DK1474067T4 (en) 2017-10-16
US20030109473A1 (en) 2003-06-12
EA200301323A1 (ru) 2005-06-30
NO20035762L (no) 2004-02-02
CN1551781A (zh) 2004-12-01
US6846477B2 (en) 2005-01-25
PE20030285A1 (es) 2003-03-27
BG66481B1 (bg) 2015-02-27
PT2842569T (pt) 2019-06-17
EP1474067B1 (en) 2008-10-29
PT2027873E (pt) 2015-11-03
JP2005515162A (ja) 2005-05-26
IS7076A (is) 2003-12-15
EP2842569A1 (en) 2015-03-04
MA27047A1 (fr) 2004-12-20
PA8549701A1 (es) 2003-01-24
EP2027873A1 (en) 2009-02-25
EP2027873B1 (en) 2015-09-09
DK2842569T3 (da) 2019-05-20
HU230246B1 (hu) 2015-11-30
EP1474067B2 (en) 2017-08-16
PT1474067E (pt) 2008-11-14
TWI329514B (en) 2010-09-01
HK1134900A1 (zh) 2010-05-20
KR20040030785A (ko) 2004-04-09
DK1474067T3 (da) 2008-12-08
HK1068250A1 (en) 2005-04-29
UY27366A1 (es) 2003-04-30
DE60229666D1 (de) 2008-12-11
WO2003003941A3 (en) 2004-07-29
BG108546A (bg) 2005-02-28
IL159349A0 (en) 2004-06-01
ES2729579T3 (es) 2019-11-04
EP2027873B8 (en) 2015-11-11
CA2451626A1 (en) 2003-01-16
HK1207584A1 (en) 2016-02-05
ES2550458T3 (es) 2015-11-10
AR034678A1 (es) 2004-03-03
EP1474067A4 (en) 2005-08-10
UA78707C2 (en) 2007-04-25
CN101524532B (zh) 2014-03-19
GT200200138A (es) 2003-05-15
OA12638A (en) 2006-06-15
CA2451626C (en) 2011-05-31
ES2312580T5 (es) 2017-12-11
HK1180224A1 (zh) 2013-10-18
ES2312580T3 (es) 2009-03-01
NO342654B1 (no) 2018-06-25
SK288010B6 (sk) 2012-10-02
TNSN03155A1 (fr) 2005-12-23
CN102872456B (zh) 2016-01-20
AU2002309109B2 (en) 2007-12-13
PL373367A1 (en) 2005-08-22
CN101524532A (zh) 2009-09-09
EP2842569B1 (en) 2019-04-10
CZ20033466A3 (cs) 2005-06-15
ZA200309698B (en) 2014-04-30
SK15792003A3 (sk) 2005-09-08
EP1474067A2 (en) 2004-11-10
CN1551781B (zh) 2013-01-02
NZ530106A (en) 2007-06-29

Similar Documents

Publication Publication Date Title
DOP2002000431A (es) Vacunación en dosis unica con mycoplasma hyopneumoniae
AR034677A1 (es) Vacuna de mycoplasma hyopneumoniae y metodos para reducir la neumonia por mycoplasma bovis en el ganado
UY27365A1 (es) Vacuna de mycoplasma bovis y métodos para reducir la neumonía en animales
RU2349342C2 (ru) Менингококковые вакцины для введения через слизистую оболочку
ES2118815T3 (es) Virus de la seudorrabia, s-prv-155, atenuado y obtenido por ingenieria genetica y sus usos.
BRPI0010612B8 (pt) vacinas
CY1111916T1 (el) Εμβολιο ζωντανου εξασθενημενου ροταϊου για χορηγηση απο του στοματος
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
AR039164A1 (es) Sales de venlafaxina de baja solubilidad en agua
AR054844A1 (es) Vacuna contra lawsonia y metodos de uso de la misma
DE60331412D1 (de) Hiv-vakzine und anwendungsverfahren
JP3701304B2 (ja) 皮膚糸状菌症用ワクチン
AR036355A1 (es) Modelo de exposicion a mycoplasma bovis, para evaluar la eficacia de potenciales vacunas
BRPI0411815A (pt) vacinas contra neisseria meningitidis do tipo y e suas combinações meningocócicas
AR053661A1 (es) Peptido para entregar vacunas via mucosas
BR0312640A (pt) Formulação contra mycoplasma gallisepticum
AR048671A1 (es) Procedimiento de vacunacion contra la infeccion testicular por bvdv
HN2002000163A (es) Vacunacion en dosis unica con mycoplasma hyopneumoniae
CY1116862T1 (el) Εμβολιασμος μιας δοσης me mycoplasma hyopneumoniae
TH64472A (th) การให้วัคซีนขนาดยาเดียวที่มี Mycoplasma Hyopneumoniae
RU2258501C2 (ru) Способ применения этидия бромистого для лечения пироплазмоза лошадей
Warrell et al. An attempt to treat rabies encephalitis in monkeys with intrathecal live rabies virus RV 675
Roy et al. A preliminary study of recombinant human interferon-α-2a activity against rabies virus in murine model
UA57299A (uk) Спосіб виготовлення вакцини проти вірусної геморагічної хвороби кролів
TH77235A (th) วัคซีน Mycoplasma bovis และวิธีสำหรับการลดปอดบวมในสัตว์